Organigram (NASDAQ:OGI – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.
Organigram (NASDAQ:OGI – Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The company reported ($0.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.04). Organigram had a negative net margin of 173.48% and a negative return on equity of 30.94%. The firm had revenue of $26.78 million for the quarter, compared to analysts’ expectations of $28.61 million. On average, analysts expect Organigram to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Organigram Stock Down 2.2 %
NASDAQ:OGI opened at $1.76 on Thursday. The company’s 50 day moving average price is $2.05 and its 200-day moving average price is $1.69. Organigram has a 52 week low of $0.97 and a 52 week high of $2.91. The stock has a market cap of $181.93 million, a price-to-earnings ratio of -2.20 and a beta of 1.07.
Analyst Ratings Changes
View Our Latest Report on Organigram
About Organigram
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
See Also
- Five stocks we like better than Organigram
- 3 Best Fintech Stocks for a Portfolio Boost
- How to Bet on a Large Stock Price Move with an Options Strangle
- How to Buy Cheap Stocks Step by Step
- Shopify Stock Took a Breather, Markets Stay Bullish On its Future
- Stock Trading Terms – Stock Terms Every Investor Needs to Know
- No New Highs for Cloudflare in 2024
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.